fulvestrant puren 250 mg injektionslösung in einer fertigspritze
eugia pharma (malta) limited (1010127) - injektionslösung in einer fertigspritze - 250 mg
faslodex
astrazeneca ab - fulvestrant - brustgeschwulste - endokrine therapie, antiöstrogene - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. in prä - oder perimenopausalen frauen, die kombination der behandlung mit palbociclib sollte in kombination mit einem luteinisierendes hormon releasing-hormon (lhrh) - agonisten.
fulvestrant stada 250 mg injektionslösung in einer fertigspritze
bb farma s.r.l. (8126628) - injektionslösung in einer fertigspritze - 250 mg
fulvestrant ratiopharm 250 mg injektionslösung in einer fertigspritze
bb farma s.r.l. (8126628) - injektionslösung in einer fertigspritze - 250 mg
fulvestrant reddy 250 mg inj. sol. i.m. pre-filled syr.
fulvestrant reddy 250 mg sol. inj. i.m. ser. préremplie
fulvestrant reddy 250 mg inj. opl. i.m. voorgev. spuit
fulvestrant eugia 250 mg inj. sol. i.m. pre-filled syr.
fulvestrant eugia 250 mg inj. opl. i.m. voorgev. spuit
fulvestrant eugia 250 mg sol. inj. i.m. ser. préremplie